Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review)
- Authors:
- Kangle Feng
- Chunhua Liu
- Weixi Wang
- Piaoping Kong
- Zhihua Tao
- Weiwei Liu
-
Affiliations: Department of Blood Transfusion, Shaoxing Central Hospital, Shaoxing, Zhejiang 312030, P.R. China, Department of Blood Transfusion, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of Laboratory Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China - Published online on: September 20, 2023 https://doi.org/10.3892/ijo.2023.5575
- Article Number: 127
-
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar | |
|
Mitsuzuka K and Arai Y: Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 25:45–53. 2018. View Article : Google Scholar | |
|
Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 22:232–240. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Sartor O: Androgen deprivation therapy in prostate cancer: New findings and questions for the future. Lancet Oncol. 20:176–177. 2019. View Article : Google Scholar | |
|
Bennett NC, Gardiner RA, Hooper JD, Johnson DW and Gobe GC: Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 42:813–827. 2010. View Article : Google Scholar | |
|
Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schröder FH and van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 144:735–746. 1994.PubMed/NCBI | |
|
Crona DJ and Whang YE: Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 9:672017. View Article : Google Scholar : PubMed/NCBI | |
|
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA and Visakorpi T: Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69:8141–8149. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C and Balk SP: Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 18:R175–R182. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cao XL, Song XM, Yu WC, Chen YQ, Wei YY, Liu YL and Lu KQ: Expression of pituitary tumor-transforming gene 1 during the development of androgen-independent prostate cancer. Zhonghua Nan Ke Xue. 22:686–691. 2016.In Chinese. PubMed/NCBI | |
|
Cao S, Zhan Y and Dong Y: Emerging data on androgen receptor splice variants in prostate cancer. Endocr Relat Cancer. 23:T199–T210. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hoang DT, Iczkowski KA, Kilari D, See W and Nevalainen MT: Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 8:3724–3745. 2017. View Article : Google Scholar : | |
|
Kumar R: Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target. J Cancer. 11:696–701. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD and Szmulewitz RZ: Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 5:72–89. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, Duan X, Liao Z, Chen Y, Liu C, et al: SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer. 117:1139–1153. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Crick F: Central dogma of molecular biology. Nature. 227:561–563. 1970. View Article : Google Scholar : PubMed/NCBI | |
|
Macklin A, Khan S and Kislinger T: Recent advances in mass spectrometry based clinical proteomics: Applications to cancer research. Clin Proteomics. 17:172020. View Article : Google Scholar : PubMed/NCBI | |
|
Intasqui P, Bertolla RP and Sadi MV: Prostate cancer proteomics: Clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics. 15:65–79. 2018. View Article : Google Scholar | |
|
Chen YT, Tsai CH, Chen CL, Yu JS and Chang YH: Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J Food Drug Anal. 27:387–403. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mantsiou A, Vlahou A and Zoidakis J: Tissue proteomics studies in the investigation of prostate cancer. Expert Rev Proteomics. 15:593–611. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kong P, Zhang L, Zhang Z, Feng K, Sang Y, Duan X, Liu C, Sun T, Tao Z and Liu W: Emerging proteins in CRPC: Functional roles and clinical implications. Front Oncol. 12:8738762022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen WY, Tsai YC, Siu MK, Yeh HL, Chen CL, Yin JJ, Huang J and Liu YN: Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. Oncogene. 36:6213–6224. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Beketova E, Fang S, Owens JL, Liu S, Chen X, Zhang Q, Asberry AM, Deng X, Malola J, Huang J, et al: Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer. Cancer Res. 80:4904–4917. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Wang M, Du Y, Liu X, Weng X and Li C: 4-1BBL has a possible role in mediating castration-resistant conversion of prostate cancer via up-regulation of androgen receptor. J Cancer. 10:2464–2471. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Özturan D, Morova T and Lack NA: Androgen receptor-mediated transcription in prostate cancer. Cells. 11:8982022. View Article : Google Scholar : PubMed/NCBI | |
|
Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, et al: Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst. 108:djw0052016. View Article : Google Scholar | |
|
Shiota M, Sekino Y, Tsukahara S, Abe T, Kinoshita F, Imada K, Ueda S, Ushijima M, Nagakawa S, Matsumoto T, et al: Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. Cancer Sci. 112:323–330. 2021. View Article : Google Scholar | |
|
Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y and Naito S: Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer. 18:505–517. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T and Naito S: Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene. 29:237–250. 2010. View Article : Google Scholar | |
|
Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S and Kohno K: Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 68:98–105. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nikhil K, Chang L, Viccaro K, Jacobsen M, McGuire C, Satapathy SR, Tandiary M, Broman MM, Cresswell G, He YJ, et al: Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer. Cancer Lett. 448:182–196. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kivinummi K, Urbanucci A, Leinonen K, Tammela TLJ, Annala M, Isaacs WB, Bova GS, Nykter M and Visakorpi T: The expression of AURKA is androgen regulated in castrationresistant prostate cancer. Sci Rep. 7:179782017. View Article : Google Scholar | |
|
Shafi AA, Yen AE and Weigel NL: Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 140:223–238. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, et al: Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 15:270–282. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, Li W, Guo Z, Xu K, Kim O, et al: Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res. 70:5587–5596. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Federer-Gsponer JR, Quintavalle C, Müller DC, Dietsche T, Perrina V, Lorber T, Juskevicius D, Lenkiewicz E, Zellweger T, Gasser T, et al: Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. J Pathol. 245:74–84. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, et al: The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 23:332–346. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin HK, Wang L, Hu YC, Altuwaijri S and Chang C: Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21:4037–4048. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hao J, Ci X, Wang Y, Choi SYC, Sullivan SE, Xue H, Wu R, Dong X, Haegert AM, Collins CC, et al: GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells. Int J Cancer. 148:469–480. 2021. View Article : Google Scholar | |
|
Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, et al: Patient-derived hormone-naive prostate cancer xenograft models reveal growth factor receptor bound protein 10 as an androgen receptor-repressed gene driving the development of castration-resistant prostate cancer. Eur Urol. 73:949–960. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ding G, Wang J, Feng C, Jiang H, Xu J and Ding Q: Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity. Oncotarget. 7:64309–64317. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Gu Y, Hui K, Huang J, Xu S, Wu S, Li L, Fan J, Wang X, Hsieh JT, et al: AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol Oncol. 36:472.e11–472.e20. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Ma T, Zhou J, Gao W, Li Y, Yu S, Wang Y and Chan FL: Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis. Theranostics. 10:4201–4216. 2020. View Article : Google Scholar : | |
|
Miyazaki Y, Teramoto Y, Shibuya S, Goto T, Okasho K, Mizuno K, Uegaki M, Yoshikawa T, Akamatsu S, Kobayashi T, et al: Consecutive prostate cancer specimens revealed increased aldoketo reductase family 1 member C3 expression with progression to castration-resistant prostate cancer. J Clin Med. 8:6012019. View Article : Google Scholar | |
|
Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML and Chinni SR: ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells. Clin Cancer Res. 21:2569–2579. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jing Y, Nguyen MM, Wang D, Pascal LE, Guo W, Xu Y, Ai J, Deng FM, Masoodi KZ, Yu X, et al: DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene. 37:638–650. 2018. View Article : Google Scholar : | |
|
Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J and Han B: The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene. 34:4735–4745. 2015. View Article : Google Scholar | |
|
Yamamoto S, Takayama KI, Obinata D, Fujiwara K, Ashikari D, Takahashi S and Inoue S: Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer. Cancer Sci. 110:3476–3485. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Qin J, Lee HJ, Wu SP, Lin SC, Lanz RB, Creighton CJ, DeMayo FJ, Tsai SY and Tsai MJ: Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest. 124:5013–5026. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Teng M, Zhou S, Cai C, Lupien M and He HH: Pioneer of prostate cancer: Past, present and the future of FOXA1. Protein Cell. 12:29–38. 2021. View Article : Google Scholar : | |
|
Xu Y, Song Q, Pascal LE, Zhong M, Zhou Y, Zhou J, Deng FM, Huang J and Wang Z: DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. Prostate. 79:657–666. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Na AY, Choi S, Yang E, Liu KH, Kim S, Jung HJ, Choe Y, Ha YS, Kwon TG, Lee JN and Lee S: Characterization of novel progression factors in castration-resistant prostate cancer based on global comparative proteome analysis. Cancers (Basel). 13:34322021. View Article : Google Scholar : PubMed/NCBI | |
|
Jain RK, Mehta RJ, Nakshatri H, Idrees MT and Badve SS: High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 58:766–772. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Tindall DJ and Huang H: Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci. 10:614–619. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng S, Prieto-Dominguez N, Yang S, Connelly ZM, StPierre S, Rushing B, Watkins A, Shi L, Lakey M, Baiamonte LB, et al: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 23:661–669. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y and Dong J: The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 35:1350–1362. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kuser-Abali G, Alptekin A, Lewis M, Garraway IP and Cinar B: YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun. 6:81262015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HC, Ou CH, Huang YC, Hou PC, Creighton CJ, Lin YS, Hu CY and Lin SC: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 40:2407–2421. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA and Burnstein KL: Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol. 22:597–608. 2008. View Article : Google Scholar | |
|
Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:280–285. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Figel S and Gelman IH: Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem. 11:607–616. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MH, Kundu JK, Keum YS, Cho YY, Surh YJ and Choi BY: Resveratrol inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol Ther (Seoul). 22:426–430. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SO, Lou W, Hou M, de Miguel F, Gerber L and Gao AC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res. 9:370–376. 2003.PubMed/NCBI | |
|
Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R and Bjartell A: Expression of STAT3 in prostate cancer metastases. Eur Urol. 71:313–316. 2017. View Article : Google Scholar : | |
|
Yang F, Yuan C, Wu D, Zhang J and Zhou X: IRE1α expedites the progression of castration-resistant prostate cancers via the positive feedback loop of IRE1α/IL-6/AR. Front Oncol. 11:6711412021. View Article : Google Scholar | |
|
Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A and Yasui W: Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients. Prostate. 79:234–242. 2019. View Article : Google Scholar | |
|
Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, et al: Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. Int J Cancer. 146:577–588. 2020. View Article : Google Scholar | |
|
Offermann A, Joerg V, Becker F, Roesch MC, Kang D, Lemster AL, Tharun L, Behrends J, Merseburger AS, Culig Z, et al: Inhibition of cyclin-dependent kinase 8/cyclin-dependent kinase 19 suppresses its pro-oncogenic effects in prostate cancer. Am J Pathol. 192:813–823. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jia L, Wu D, Wang Y, You W, Wang Z, Xiao L, Cai G, Xu Z, Zou C, Wang F, et al: Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Oncogene. 37:3340–3355. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sooreshjani MA, Nikhil K, Kamra M, Nguyen DN, Kumar D and Shah K: LIMK2-NKX3.1 engagement promotes castration-resistant prostate cancer. Cancers (Basel). 13:23242021. View Article : Google Scholar : PubMed/NCBI | |
|
Lv S, Song Q, Chen G, Cheng E, Chen W, Cole R, Wu Z, Pascal LE, Wang K, Wipf P, et al: Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest. 131:e1413352021. View Article : Google Scholar : | |
|
Wu H, You L, Li Y, Zhao Z, Shi G, Chen Z, Wang Z, Li X, Du S, Ye W, et al: Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance. Cancer Res. 80:2927–2939. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wolff DW, Xie Y, Deng C, Gatalica Z, Yang M, Wang B, Wang J, Lin MF, Abel PW and Tu Y: Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer. 130:1521–1531. 2012. View Article : Google Scholar | |
|
Linder A, Larsson K, Welén K and Damber JE: RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer. Prostate. 80:799–810. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF and Tu Y: Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 25:3719–3734. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Hu X, Gao Y, Tang Q, Zhao Z, Xi W, Yang F, Zhang W, Song Y, Song B, et al: MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3β signaling impedes castration-resistant prostate cancer growth. Aging (Albany NY). 11:10644–10663. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jung C, Kim RS, Zhang HJ, Lee SJ and Jeng MH: HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 64:9185–9192. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD and McDonnell DP: The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 36:405–416. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Puca L, Vlachostergios PJ and Beltran H: Neuroendocrine differentiation in prostate cancer: Emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 9:a0305932019. View Article : Google Scholar | |
|
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, et al: Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 32:474–489.e6. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Makino T, Izumi K and Mizokami A: Undesirable status of prostate cancer cells after intensive inhibition of AR signaling: Post-AR Era of CRPC treatment. Biomedicines. 9:4142021. View Article : Google Scholar : PubMed/NCBI | |
|
Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 19:1997–2007. 2020.PubMed/NCBI | |
|
Shorning BY, Dass MS, Smalley MJ and Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 21:45072020. View Article : Google Scholar : PubMed/NCBI | |
|
Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C and Edwards J: Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer. 104:1920–1928. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong S, Peng S, Chen Z, Chen Z and Luo JL: Choosing kinase inhibitors for androgen deprivation therapy-resistant prostate cancer. Pharmaceutics. 14:4982022. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung S, Jain P, So J, Shahidi S, Chung S and Koritzinsky M: p38 MAPK inhibition mitigates hypoxia-induced AR signaling in castration-resistant prostate cancer. Cancers (Basel). 13:8312021. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng C, Wang J, Xu P, Zhang K, Xin Z, Zhao H, Ji Z, Zhang M, Wang D, He Y, et al: Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer. Nat Cancer. 3:565–580. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Verhoef EI, Kolijn K, De Herdt MJ, van der Steen B, Hoogland AM, Sleddens HF, Looijenga LH and van Leenders GJ: MET expression during prostate cancer progression. Oncotarget. 7:31029–31036. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ibuki N, Ghaffari M, Pandey M, Iu I, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME and Cox ME: TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 133:1955–1966. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yu M, Gipp J, Yoon JW, Iannaccone P, Walterhouse D and Bushman W: Sonic hedgehog-responsive genes in the fetal prostate. J Biol Chem. 284:5620–5629. 2009. View Article : Google Scholar : | |
|
Gao Y, Li L, Li T, Ma L, Yuan M, Sun W, Cheng HL, Niu L, Du Z, Quan Z, et al: Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1. Int J Oncol. 54:2054–2068. 2019.PubMed/NCBI | |
|
Nguyen DP, Li J and Tewari AK: Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int. 113:986–992. 2014. View Article : Google Scholar | |
|
Niwa H, Burdon T, Chambers I and Smith A: Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12:2048–2060. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YN, Niu S, Chen WY, Zhang Q, Tao Y, Chen WH, Jiang KC, Chen X, Shi H, Liu A, et al: Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46. Clin Cancer Res. 25:4128–4140. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cariaga-Martinez AE, Lorenzati MA, Riera MA, Cubilla MA, De La Rossa A, Giorgio EM, Tiscornia MM, Gimenez EM, Rojas ME, Chaneton BJ, et al: Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol. 2009:7238312009. View Article : Google Scholar : PubMed/NCBI | |
|
Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, et al: Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 26:131–146. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL and Ho SM: Targeting GPR30 with G-1: A new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer. 21:903–914. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Zong J, Peng Y, Shi J, Du X, Liu H, Shen Y, Cao J, Jia B, Liu F and Zhang J: GPR30 knockdown weakens the capacity of CAF in promoting prostate cancer cell invasion via reducing macrophage infiltration and M2 polarization. J Cell Biochem. May 3–2021.Epub ahead of print. View Article : Google Scholar | |
|
Chan QKY, Lam HM, Ng CF, Lee AYY, Chan ES, Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 17:1511–1523. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Edlind MP and Hsieh AC: PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H, Szarvas T, Hadaschik B, Lückerath K, Herrmann K, et al: Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci. 22:74312021. View Article : Google Scholar : PubMed/NCBI | |
|
Caromile LA and Shapiro LH: PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Mol Cell Oncol. 4:e13211682017. View Article : Google Scholar : PubMed/NCBI | |
|
Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, Meller J and Thelen P: Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 5:662015. View Article : Google Scholar : PubMed/NCBI | |
|
Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC and Artigas Guix C; Oncology Working Group of the Spanish Society of Nuclear Medicine and Molecular Imaging: The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. Rev Esp Med Nucl Imagen Mol (Engl Ed). 41:126–135. 2022.PubMed/NCBI | |
|
Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G and Liu J: The added value of 18F-FDG PET/CT compared with 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer. J Nucl Med. 63:69–75. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Weber M, Hadaschik B, Ferdinandus J, Rahbar K, Bögemann M, Herrmann K, Fendler WP and Kesch C: Prostate-specific membrane antigen-based imaging of castration-resistant prostate cancer. Eur Urol Focus. 7:279–287. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, et al: Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 76:469–478. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W and Matsubara A: TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer. Int J Mol Sci. 20:39362019. View Article : Google Scholar : PubMed/NCBI | |
|
Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, Kheuang L, Coppolani E, Ali A, Bibeau F, et al: Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer. 101:951–956. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Maahs L, Sanchez BE, Gupta N, Van Harn M, Barrack ER, Reddy PV and Hwang C: Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS One. 14:e02225102019. View Article : Google Scholar | |
|
Alfano A, Xu J, Yang X, Deshmukh D and Qiu Y: SRC kinase-mediated tyrosine phosphorylation of TUBB3 regulates its stability and mitotic spindle dynamics in prostate cancer cells. Pharmaceutics. 14:9322022. View Article : Google Scholar : PubMed/NCBI | |
|
Korkes F, de Castro MG, de Cassio Zequi S, Nardi L, Del Giglio A and de Lima Pompeo AC: Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue. BJU Int. 113:822–829. 2014. View Article : Google Scholar | |
|
Lin SL, Chang D and Ying SY: Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis. 28:310–320. 2007. View Article : Google Scholar | |
|
Hannan FM, Kallay E, Chang W, Brandi ML and Thakker RV: The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 15:33–51. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bery F, Cancel M, Chantôme A, Guibon R, Bruyère F, Rozet F, Mahéo K and Fromont G: The calcium-sensing receptor is a marker and potential driver of neuroendocrine differentiation in prostate cancer. Cancers (Basel). 12:8602020. View Article : Google Scholar : PubMed/NCBI | |
|
Ahearn TU, Tchrakian N, Wilson KM, Lis R, Nuttall E, Sesso HD, Loda M, Giovannucci E, Mucci LA, Finn S and Shui IM: Calcium-sensing receptor tumor expression and lethal prostate cancer progression. J Clin Endocrinol Metab. 101:2520–2527. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamura A, Nayeem MJ and Sato M: Calcilytics inhibit the proliferation and migration of human prostate cancer PC-3 cells. J Pharmacol Sci. 139:254–257. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liao J, Schneider A, Datta NS and McCauley LK: Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 66:9065–9073. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and Xu Y: miR-539 inhibits prostate cancer progression by directly targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI | |
|
Ebhardt HA, Root A, Liu Y, Gauthier NP, Sander C and Aebersold R: Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. NPJ Syst Biol Appl. 4:262018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, et al: MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell. 151:937–950. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Adler D, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, et al: MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocr Relat Cancer. 21:663–675. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Adler D, Menon R, Braun M, Offermann A, Queisser A, Boehm D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, et al: MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer. Int J Cancer. 135:19–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, et al: MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget. 8:7964–7976. 2017. View Article : Google Scholar : | |
|
Chen Z, Gao H, Dong Z, Shen Y, Wang Z, Wei W, Yi J, Wang R, Wu N and Jin S: NRP1 regulates radiation-induced EMT via TGF-β/Smad signaling in lung adenocarcinoma cells. Int J Radiat Biol. 96:1281–1295. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, et al: Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. 36:3417–3427. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Makino Y, Kamiyama Y, Brown JB, Tanaka T, Murakami R, Teramoto Y, Goto T, Akamatsu S, Terada N, Inoue T, et al: Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1. Commun Biol. 5:2992022. View Article : Google Scholar : PubMed/NCBI | |
|
Bland T, Wang J, Yin L, Pu T, Li J, Gao J, Lin TP, Gao AC and Wu BJ: WLS-Wnt signaling promotes neuroendocrine prostate cancer. iScience. 24:1019702021. View Article : Google Scholar : PubMed/NCBI | |
|
Sengupta D, Zeng L, Li Y, Hausmann S, Ghosh D, Yuan G, Nguyen TN, Lyu R, Caporicci M, Morales Benitez A, et al: NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Mol Cell. 81:4481–4492.e9. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Filon M, Gawdzik J, Truong A, Allen G, Huang W, Khemees T, Machhi R, Lewis P, Yang B, Denu J and Jarrard D: Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype. Br J Cancer. 125:247–254. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX and Chen HW: Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 32:3121–3131. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YR, Oh KJ, Park RY, Xuan NT, Kang TW, Kwon DD, Choi C, Kim MS, Nam KI, Ahn KY and Jung C: HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer. 9:1242010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YR, Kang TW, To PK, Xuan Nguyen NT, Cho YS, Jung C and Kim MS: HOXB13-mediated suppression of p21WAF1/CIP1 regulates JNK/c-Jun signaling in prostate cancer cells. Oncol Rep. 35:2011–2016. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, Nam KI and Jung C: HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. 33:4558–4567. 2014. View Article : Google Scholar | |
|
Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, et al: HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nat Genet. 54:670–683. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fine SW: Neuroendocrine tumors of the prostate. Mod Pathol. 31(S1): S122–S132. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V and Domingo-Domenech J: Cellular rewiring in lethal prostate cancer: The architect of drug resistance. Nat Rev Urol. 17:292–307. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y and Wang Y, Ci X, Choi SYC, Crea F, Lin D and Wang Y: Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 18:581–596. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, et al: Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 6:1806–1820. 2015. View Article : Google Scholar : | |
|
Li Y, Zhang Q, Lovnicki J, Chen R, Fazli L, Wang Y, Gleave M, Huang J and Dong X: SRRM4 gene expression correlates with neuroendocrine prostate cancer. Prostate. 79:96–104. 2019. View Article : Google Scholar | |
|
Lee AR, Che N, Lovnicki JM and Dong X: Development of neuroendocrine prostate cancers by the Ser/Arg repetitive matrix 4-mediated RNA splicing network. Front Oncol. 8:932018. View Article : Google Scholar : PubMed/NCBI | |
|
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, et al: The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 39:7465–7476. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Marine JC, Dawson SJ and Dawson MA: Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 20:743–756. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao R, Feng T, Gao L, Sun F, Zhou Q, Wang X, Liu J, Zhang W, Wang M, Xiong X, et al: PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2. J Exp Clin Cancer Res. 41:1252022. View Article : Google Scholar : PubMed/NCBI | |
|
Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, Kivinummi KK, Tammela TTL, Beuerman RW, Uusitalo H, et al: Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 9:11762018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Harvey CT, Geng H, Xue C, Chen V, Beer TM and Qian DZ: Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. Prostate. 73:1028–1037. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Blomme A, Peter C, Mui E, Rodriguez Blanco G, An N, Mason LM, Jamieson LE, McGregor GH, Lilla S, Ntala C, et al: THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Mol Med. 14:e147642022. View Article : Google Scholar : PubMed/NCBI | |
|
Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, et al: Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA. 116:631–640. 2019. View Article : Google Scholar : | |
|
El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, et al: Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res. 81:5477–5490. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, Paez A, Antico-Arciuch V, Lage-Vickers S, Hoang AG, et al: Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 40:6284–6298. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K and Diamandis EP: Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics. 12:1589–1601. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eerola SK, Kohvakka A, Tammela TLJ, Koskinen PJ, Latonen L and Visakorpi T: Expression and ERG regulation of PIM kinases in prostate cancer. Cancer Med. 10:3427–3436. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Peng HH, Wang JN, Xiao LF, Yan M, Chen SP, Wang L and Yang K: Elevated serum FGG levels prognosticate and promote the disease progression in prostate cancer. Front Genet. 12:6516472021. View Article : Google Scholar : PubMed/NCBI | |
|
Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, et al: Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci USA. 113:E6457–E6466. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Su Q and Xin L: Notch signaling in prostate cancer: Refining a therapeutic opportunity. Histol Histopathol. 31:149–157. 2016. | |
|
Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ, et al: Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol Cancer Ther. 13:2288–2302. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Babcook MA, Akgul M, Margevicius S, MacLennan GT, Fu P, Abouassaly R and Gupta S: Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study. Prostate. 78:714–723. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sawant Dessai A, Dominguez MP, Chen UI, Hasper J, Prechtl C, Yu C, Katsuta E, Dai T, Zhu B, Jung SY, et al: Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone. Cancer Res. 81:50–63. 2021. | |
|
Wang L, Li H, Li Z, Li M, Tang Q, Wu C and Lu Z: Smoothened loss is a characteristic of neuroendocrine prostate cancer. Prostate. 81:508–520. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, et al: HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. Int J Oncol. 53:99–112. 2018.PubMed/NCBI | |
|
Tan B, Chen X, Fan Y, Yang Y, Yang J and Tan L: STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis. Prostate. 81:603–611. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Vellky JE and Ricke WA: Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 22:566–575. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JY, Zeng QH, Cao PG, Xie D, Yang F, He LY, Dai YB, Li JJ, Liu XM, Zeng HL, et al: SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. Oncogene. 37:3937–3952. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S and Castellucci P: Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 62:596–604. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nussinov R, Tsai CJ and Jang H: Anticancer drug resistance: An update and perspective. Drug Resist Updat. 59:1007962021. View Article : Google Scholar : PubMed/NCBI | |
|
Genovese I, Ilari A, Assaraf YG, Fazi F and Colotti G: Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat. 32:23–46. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shahar N and Larisch S: Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat. 52:1007122020. View Article : Google Scholar : PubMed/NCBI | |
|
Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR and Vasconcelos MH: The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 46:1006452019. View Article : Google Scholar : PubMed/NCBI | |
|
Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA, Wagner S, Stamm C, Buness A, Chatenay-Rivauday C, et al: Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2:948–959. 2012. View Article : Google Scholar : PubMed/NCBI |
